Evidence map›Paper›PMID 35986643›Full record

ArticleImmunology2023

Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.

Bao Ying Chen, Jessica R Salas, Alyssa O Trias, Arely Perez Rodriguez, Jonathan E Tsang, Miriam Guemes, Thuc M Le, Zoran Galic, H Michael Shepard, Lawrence Steinman and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Bao Ying ChenDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Jessica R SalasDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Alyssa O TriasDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Arely Perez RodriguezDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Jonathan E TsangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Miriam GuemesDepartment of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Thuc M LeDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Zoran GalicDepartment of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
H Michael ShepardEnosi Life Sciences, Eugene, Oregon, USA.ORCID 0000-0003-1868-9179
Lawrence SteinmanDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Owen N WitteDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Caius G RaduDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Kenneth A SchultzTrethera Corporation, Los Angeles, California, USA.
Peter M ClarkDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-0786-9054
University of California, Los Angeles · USCalifornia NanoSystems Institute · USEugene Research Institute · USStanford University · USTrex (United States) · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Non-invasive imaging of brain infiltrating T lymphocytes in a mouse model of experimental autoimmune encephalomyelitis with PETR01NS112287 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CLARK, PETER MICHAEL · 2019 to 2023
$1.7M
Imaging immune-mediated liver rejection with Positron Emission TomographyR21AI119916 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CLARK, PETER MICHAEL · 2015 to 2016
$424k
NCI NIH HHS P30 CA016042NIAID NIH HHS P30 AI028697NIAID NIH HHS R21 AI119916NINDS NIH HHS R01 NS112287
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an autoimmune disease driven by lymphocyte activation against myelin autoantigens in the central nervous system leading to demyelination and neurodegeneration. The deoxyribonucleoside salvage pathway with the rate-limiting enzyme deoxycytidine kinase (dCK) captures extracellular deoxyribonucleosides for use in intracellular deoxyribonucleotide metabolism. Previous studies have shown that deoxyribonucleoside salvage activity is enriched in lymphocytes and required for early lymphocyte development. However, specific roles for the deoxyribonucleoside salvage pathway and dCK in autoimmune diseases such as MS are unknown. Here we demonstrate that dCK activity is necessary for the development of clinical symptoms in the MOG

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsDeoxycytidine KinaseDisease Models, AnimalLymphocytesMiceMice, Inbred C57BLDeoxycytidine KinaseautoimmunityEAE/MSimagingnucleotide metabolism

Identifiers

PMID35986643
PMCPMC9844239
OpenAlexW4293071129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.